Sucampo Pharmaceuticals, Inc.  

(Public, NASDAQ:SCMP)   Watch this stock  
Find more results for SCMP
15.06
-0.90 (-5.64%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.04 - 16.13
52 week 5.80 - 16.50
Open 15.87
Vol / Avg. 273,149.00/313,888.00
Mkt cap 667.90M
P/E 108.31
Div/yield     -
EPS 0.14
Shares 44.35M
Beta 1.68
Inst. own 25%
Feb 24, 2015
Q4 2014 Sucampo Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Feb 10, 2015
Sucampo Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - 1:30PM EST - Add to calendar
Dec 2, 2014
Sucampo Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 18, 2014
Sucampo Pharmaceuticals Inc at Stifel Healthcare Conference - Webcast
Nov 12, 2014
Sucampo Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Nov 6, 2014
Q3 2014 Sucampo Pharmaceuticals Inc Earnings Release
Nov 6, 2014
Q3 2014 Sucampo Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.70% 7.16%
Operating margin 11.58% 10.26%
EBITD margin - 11.92%
Return on average assets 4.14% 4.85%
Return on average equity 8.42% 12.59%
Employees 77 -
CDP Score - -

Address

3RD FLOOR, 4520 EAST-WEST HIGHWAY
BETHESDA, MD 20814
United States - Map
+1-301-9613400 (Phone)
+1-301-9613440 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company is focused on developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and other potential therapeutic applications of its drug technologies. The Company�s products include AMITIZA (Lubiprostone) is approved to treat Chronic Idiopathic Constipation (CIC) in adults; RESCULA (Unoprostone isopropyl) is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; Intravenous (IV) and Oral (PO) Ion Channel Activators for lumbar spinal stenosis; and cobiprostone for oral mucositis. The Company has the following direct and indirect wholly owned subsidiaries: Sucampo Pharma Americas, LLC, Sucampo Pharma Europe, Sucampo Pharma, Ltd and Sucampo AG.

Officers and directors

Daniel P. Getman Ph.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Peter Greenleaf Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Thomas J. Knapp Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Matthias Alder LL.M Executive Vice President - Business Development & Licensing
Age: 49
Bio & Compensation  - Reuters
Stanley G. Miele Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
Age: 50
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President - Regulatory Affairs
Age: 54
Bio & Compensation  - Reuters
Andrew P. Smith Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
Peter A. Kiener Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Anthony C. Celeste Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Gayle R. Dolecek Director
Age: 71
Bio & Compensation  - Reuters